Stockscreener 앱 받기
6.60
0.90%
-0.06
시장 영업 전:
7.27
0.67
+10.15%
전일 마감가:
$6.66
열려 있는:
$6.67
하루 거래량:
1.25M
Relative Volume:
0.57
시가총액:
$667.11M
수익:
-
순이익/손실:
$-29.07M
주가수익비율:
-22.76
EPS:
-0.29
순현금흐름:
$-31.85M
1주 성능:
-4.35%
1개월 성능:
+24.53%
6개월 성능:
+126.80%
1년 성능:
+150.00%
1일 변동 폭
$6.37
$6.78
1주일 범위
$6.37
$7.24
52주 변동 폭
$2.30
$7.39
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
TRVI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
6.60 | 667.11M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
MetLife Investment Management LLC Purchases 19,857 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo
Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations - Investing.com
Trevi Therapeutics (TRVI): Promising Data and Strategic Advances | TRVI Stock News - GuruFocus
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings: EPS of -$0.09 Beats Estimate, Reports $10.3 Million Net Loss - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | TRVI Stock News - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
Barclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts - Defense World
Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Invesco Ltd. Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Renaissance Technologies LLC Acquires 29,700 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - Defense World
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 - StreetInsider
Trevi Therapeutics to Report First Quarter 2025 Financial Result - GuruFocus
Trevi Therapeutics Inc [TRVI] Records 50-Day SMA of $5.77 - knoxdaily.com
Indo-Asian News Service - Indo-Asian News Service (IANS)
A look at TRVI’s current quarter earnings estimates - uspostnews.com
TRVI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Quarterly Metrics: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX
SEC Form DEF 14A filed by Trevi Therapeutics Inc. - Quantisnow
JPMorgan Chase & Co. Boosts Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Recent Insider Activity Suggests Potential Gains for Trevi Therapeutics Inc (TRVI) - knoxdaily.com
What is Trevi Therapeutics Inc (TRVI) Stock Return on Shareholders’ Capital? - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Has $5.35 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Quarterly Snapshot: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics Inc (TRVI)’s results reveal risk - uspostnews.com
Stifel maintains Trevi Therapeutics stock Buy rating, $15 target By Investing.com - Investing.com Canada
12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Acquired by Raymond James Financial Inc. - Defense World
American Century Companies Inc. Buys 24,153 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of “Buy” by Analysts - Defense World
Trevi Therapeutics Sees Unusually Large Options Volume (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at Needham & Company LLC - Defense World
Trevi Therapeutics at 24th Annual Needham: Strategic Advances in Cough Treatments - Investing.com Canada
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha
Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
Trevi Therapeutics to Participate in Upcoming April Investor Conferences - The Malaysian Reserve
Trevi's Game-Changing Chronic Cough Treatment Takes Center Stage at 3 Major Healthcare Conferences - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Growth in Short Interest - Defense World
Charles Schwab Investment Management Inc. Has $713,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
What to expect from TRVI’s earnings report this quarter? - uspostnews.com
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones - Proactive financial news
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones | NASDAQ:TRVI - Proactive Investors
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock By Investing.com - Investing.com Australia
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock - Investing.com
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock By Investing.com - Investing.com South Africa
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock - Investing.com
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.73%
1.07%
자본화:
|
볼륨(24시간):